Adequacy of Perioperative Cefazolin for Surgery Antibiotic Prophylaxis in Obese Patients

Phase 4

Withdrawn

Brief Summary: The population continues to increase in weight. Currently there are no guidelines in the dosing of cefazolin for the obese population. Standard dosing of cefazolin 2 grams for patients \<120 kg and 3 grams for patients \>120 kg is used as the dose for surgical prophylaxis. This makes no provisions for weight based dosing. There has been some recent data which states this might not be enough for the obese patients. The primary objective of this study is to determine if weight based dosing (30 mg/kg) of cefazolin as surgical prophylaxis for patients undergoing elective gastric bypass/laparoscopic Roux-en-y gastric bypass provides appropriate serum concentrations for a larger percentage of time than the current method of giving the standard 2 or 3 gram doses of cefazolin peri-operatively. The concentration of cefazolin in tissue will also be measured to help assess this question.

Detailed Description: The hypothesis of this study is that customary doses of antibiotics, when administered for perioperative surgical prophylaxis, are insufficient to achieve adequate antibiotic concentrations in blood and tissues of morbidly obese patients (defined as a BMI greater than 40 kg/m2) and that these patients are therefore placed at high risk of surgical wound infections and poor clinical outcomes. Cefazolin is a first-generation cephalosporin commonly used for perioperative surgical prophylaxis in colorectal, abdominal, bariatric, gynecologic and obstetric, or orthopedic total joint arthroplasty surgical procedures. Previous cefazolin pharmacokinetic (PK) analysis in obese patients led to conflicting results and recommendations. It is not clearly know to what extent the pharmacokinetics of cefazolin in morbidly obese patients differ from those of non-obese patients. Specific dosing guidelines are then lacking. The main objective of this study is to assess the pharmacokinetics of cefazolin in morbidly obese after administrations of a standard recommended 2-3 g dose or a weight-base 30-mg/kg dose

Recruitment & Eligibility

Inclusion Criteria

BMI greater than 40
No known history of allergy to cephalosporins
Scheduled for elective gastric bypass or laparoscopic Roux-en-y gastric bypass procedures
Able to read and understand English

Exclusion Criteria

Arm && Interventions

Group	Intervention	Description
Control group	Standard Dose Group	Standard dose group (2 g intravenous (IV) cefazolin dose for patients \<120 kg, and 3 g IV cefazolin for patients \>120 kg)
Treatment group	Weight Based Group	Weight-based dose group (30 mg/kg cefazolin IV)

Primary Outcome Measures

Name	Time	Method
Assessment of the Pharmacokinetics of Cefazolin in the Morbidly Obese	Before cefazolin admin., then at 10, 30, 60, 120, 180 minutes after injection and at wound closure.	Since the goal of perioperative antimicrobial prophylaxis is to achieve free (unbound) serum and tissue drug levels that exceed the MIC for likely pathogens across the duration of the surgical procedure, and since redosing of cefazolin is recommended every 3-4 hours, PK/PD performance of cefazolin over that time frame will be analyzed. For the purposes of this study, pharmacodynamic targets are defined as fT\>MIC (time during which free drug concentrations exceed pathogen MICs) of 100% over periods of up to 4 hours in duration. The PK/PD probability of target attainment (PTA) for pharmacodynamic goals and the cumulative fraction of response (CFR) for both cefazolin regimens will be compared. A PTA of ≥90% and a CFR of ≥ 90% for a dosage regimen (i.e., predicted to meet pharmacodynamic targets in ≥ 90% of the total bacterial population across the full range of MICs) are considered optimum.

Secondary Outcome Measures

Name	Time	Method
Incidence of surgical site infection	Within 1 month postoperatively	The incidence of surgical site infection will be monitored and compared.
Hospital length of stay	Hospital discharge	The length of time the subject is hospitalized will be monitored and compared.
Hospital readmission	Witihn 1 month after hospital discharge	Hospital readmission within 1 month postoperatively.
Incidence of adverse outcomes	Within 1 month postoperatively	Adverse outcomes in these patients will be monitored and compared.

Locations (1): University of Colorado Hospital
🇺🇸
Aurora, Colorado, United States